The complex pathology of diabetic retinopathy (DR) affects both vascular and neural tissue. The characteristics of neurodegeneration are well-described in animal models but have more recently been confirmed in the clinical setting, mostly by using non-invasive imaging approaches such as spectral domain optical coherence tomography (SD-OCT). The most frequent observations report loss of tissue in the nerve fiber layer and inner plexiform layer, confirming earlier findings from animal models. In several cases the reduction in inner retinal layers is reported in patients with little evidence of vascular lesions or macular edema, suggesting that degenerative loss of neural tissue in the inner retina can occur after relatively short durations of diabetes. Animal studies also suggest that neurodegeneration leading to retinal thinning is not limited to cell death and tissue loss but also includes changes in neuronal morphology, reduced synaptic protein expression and alterations in neurotransmission, including changes in expression of neurotransmitter receptors as well as neurotransmitter release, reuptake and metabolism. The concept of neurodegeneration as an early component of DR introduces the possibility to explore alternative therapies to prevent the onset of vision loss, including neuroprotective therapies and drugs targeting individual neurotransmitter systems, as well as more general neuroprotective approaches to preserve the integrity of the neural retina. In this review we consider some of the evidence for progressive retinal neurodegeneration in diabetes, and explore potential neuroprotective therapies.
Introduction
DR is the leading cause of vision loss in working-age adults, affecting more than 7.5 million people in the USA and approximately 190 million worldwide (Lee, Wong, & Sabanayagam, 2015) . The prevalence of DR continues to increase due to the expansion of our ageing population and increasing prevalence of diabetes (Lee, Feldman, Ostermann, Brown, & Sloan, 2003) . The clinical diagnosis of DR relies primarily on the detection of vascular lesions by ophthalmic fundus exam. The presence and distribution of microaneurysms, intraretinal hemorrhage, venous beading and neovascularization are used to define the stage of disease. DR commonly involves macular edema due to compromise of the blood retinal barrier, but the disease can progress in some cases to the proliferative form involving neovascularization. The presence and abundance of macular edema is now regularly detected by using spectral domain optical coherence tomography (SD-OCT). Using this technology, evidence from animal models of diabetes as well as clinical studies suggests that the neural retina is also affected by diabetes in ways that may have direct impact on visual perception.
In the last 15-20 years it has become apparent that the neural retina suffers from irreversible loss of neurons and degenerates in a manner analogous to that seen in other chronic neurodegenerative diseases (Barber, 2003) . This process was initially characterized by accelerated loss of neurons by apoptosis, especially within the inner retina . The retinas of both animal models and humans with diabetes also exhibit other features of neurodegenerative disease including structural and biochemical changes that can potentially alter the function of individual neurons and even result in changes to the way the neural network processes information and delivers signals to the brain (Barber, Gardner, & Abcouwer, 2011) . Current treatment of DR includes laser surgery and, more recently, intraocular injection of anti-VEGF agents have been used for both diabetic macular edema and proliferative retinopathy (Wells et al., 2015) . Anti-VEGF therapy has showed good success in treating macular edema, and is as equally effective as pan-retinal photocoagulation laser surgery in treating the proliferative disease (Network et al., 2015) . These approaches have provided increased success in stabilizing the vascular pathologies of the disease and have led to improved visual outcomes. Disease severity, as graded and staged by vascular lesions, has also been shown to regress, but it is unclear whether other changes within the retinal tissue are reversible using this approach. Laser surgery undoubtedly causes permanent damage to the retina and has been shown to induce thinning of the retinal nerve fiber layer (Lim et al., 2009) . Trials are ongoing to treat diabetic patients with anti-VEGF agents to prevent the development of DR as defined by vascular lesions, however, there has been little consideration of potential therapies targeting neurodegeneration. For the purpose of this review we will consider neurodegeneration, defined as a pathological condition effecting the structure or function of neurons, including their accelerated cell death, as discussed by Przedborski, Vila, and Jackson-Lewis (2003) .
The relationship between vascular pathology and retinal neurodegeneration is still debatable. Whether or not these two aspects of the disease are causally related or independent phenomena is not established, and direct causality should not be assumed (Barber, VanGuilder, & Gastinger, 2007; Barber et al., 2011) . It makes sense to continue to identify novel therapeutic targets that can be used to prevent the onset of DR, including the different features of neurodegeneration. Novel therapies for DR could include neuroprotective agents, as well as drugs to correct abnormalities in neurotransmitter release, uptake and neurotransmitter receptor signaling. Here we attempt to consider potential therapies for DR that target neural systems and neurodegeneration.
Diabetic retinopathy as a neurodegenerative disease: Retinal apoptosis
The most widely recognized feature of neurodegenerative disease is the accelerated loss of neurons by apoptosis. Increased frequency of apoptosis is now considered an important component of the pathology in DR. Early studies characterized the vascular lesions in postmortem specimens of human retinas (Bloodworth, 1963; Bloodworth & Molitor, 1965; Cunha-Vaz, 1978) , but some of these also identified features of degeneration a decade before the concept of apoptosis (previously called pyknosis) was even characterized as a form of cell death with well-defined biochemical features (Bloodworth, 1962; Wolter, 1961) . Later work used animal models of diabetes to identify and count individual apoptotic cells using terminal dUTP nick end labeling (TUNEL) in the vascular network isolated by trypsin digest (Mizutani, Kern, & Lorenzi, 1996) . When this approach was adapted to the entire retina as a flat-mount, a much greater number of TUNEL-positive apoptotic cells could be observed and counted, suggesting that the cell death was not limited to just the vasculature but included cells within the neural retina, such as neurons and possibly glia . The increase in apoptosis was significant even in rats after only one month of streptozotocin (STZ)-diabetes, and continuing at a fairly constant rate over a 12-month period, suggested the possibility of chronic neurodegeneration. Other studies using TUNEL confirmed the increase in apoptosis in retinas of diabetic rats and mice (Martin, Roon, Van Ells, Ganapathy, & Smith, 2004; Barber et al., 2005) , and in the KKAY mouse, which is thought to model Type II diabetes (Ning et al., 2004) . Chronically elevated intraocular pressure was found to further increase the number of diabetes-induced TUNEL-positive cells, suggesting that a combination of glaucoma and diabetes could be even more damaging to the neurons of the retina (Kanamori, Nakamura, Mukuno, Maeda, & Negi, 2004) . Since those early studies, apoptosis has been used as an endpoint in numerous animal studies modeling DR (Barber et al., 2011) . Retinal apoptosis has also been noted in several postmortem studies of human retina, thus confirming the results from animal studies (Kerrigan, Zack, Quigley, Smith, & Pease, 1997; Abu-ElAsrar, Dralands, Missotten, Al-Jadaan, & Geboes, 2004a; Barber et al., 1998) .
Other markers have been used to confirm retinal apoptosis in animal models of diabetes. The presence of cleaved caspase-3 in retinas of diabetic animals confirmed and extended the initial observations of cell death in the vasculature and neural retina of diabetic animals (Kowluru & Koppolu, 2002; Mohr, Xi, Tang, & Kern, 2002; Martin et al., 2004; Sasaki et al., 2010) , including a rat model of Type II diabetes (Yang et al., 2013) . A histological study noted that cleaved caspase-3 co-localized with cell-specific markers of neurons in whole-mount retinas from Ins2
Akita diabetic mice (Gastinger, Singh, & Barber, 2006) , and caspase-3 activity in diabetic rodent retinas was also measured biochemically . Other immunohistochemical studies have revealed that pro-apoptotic BAX, Fas and caspase-3 were upregulated in the retinal ganglion cells of diabetic donors (Podestà et al., 2000; Abu-El-Asrar, Dralands, Missotten, Al-Jadaan, & Geboes, 2004b) , whereas the anti-apoptotic BCL2 colocalized with GFAP positive cells, indicating its upregulation in Muller cells (Abu-El-Asrar et al., 2004b) . The enzyme activities of caspase-3, caspase 12, Bad and BCL2 have also been shown to increase in diabetic rodent retinas Tang et al., 2011; Dong, Jin, Lu, & Kang, 2013) . While biochemical approaches and TUNEL labeling lack cell-type specificity several histological approaches have been used to identify the cells most affected by apoptosis. Gastinger counted choline acetyltransferase-and tyrosine hydroxylase-positive cells in flat-mounted retinas to establish that the number of both cholinergic and dopaminergic amacrine cells is depleted in the Ins2
Akita diabetic mouse (Gastinger et al., 2006) , and further showed that caspase-3-positive cells were located in multiple layers of the retina including occasional cells in the outer nuclear layer, suggesting that a small number of photoreceptors may also undergo apoptosis. Another study in STZdiabetic rats suggested that a much larger number of photoreceptors die even after a short duration of diabetes (Park et al., 2003) although this result has not been replicated in other histological studies. When CFP was placed under the Thy-1 promotor in Ins2 Akita mice there was a smaller number of surviving CFP-positive cells, confirming the specific loss of retinal ganglion cells in this model (Gastinger, Kunselman, Conboy, Bronson, & Barber, 2008) . One important aspect to consider is the impact of glycemic control on diabetic complications. Animal models are often studied in the absence of exogenous insulin. A study in diabetic dogs with moderate glycemic control using insulin ameliorated the diabetes-induced loss of optic nerve axons (Howell, Mekhail, Azem, Ward, & Kern, 2013) . Similar results were found previously in rats treated with insulin , suggesting that the survival of retinal ganglion cells is determined by the severity of diabetes.
If apoptosis of neurons continues over an extended period of time there will eventually be a significant reduction in neural tissue volume. Tissue loss in the retina, being a highly topographically organized tissue, can be measured relatively easily using histological approaches. Many studies of diabetic animal models have revealed loss of the thickness of cell layers in the retina, especially the inner retina. The chronic loss of irreplaceable neurons was suggested by a reduction in the thickness of the inner plexiform and inner nuclear layers, as well as fewer large-bodied cells in the ganglion cell layer of retinas from rats that were diabetic for 7.5 months . Similar results were found by histological measurement of the retinas of Ins2 Akita diabetic mice (Barber et al., 2005; Smith et al., 2008) . Although less frequent, some studies have also reported loss of outer nuclear layer cells and consequent reductions in retinal thickness and there may be other degenerative changes affecting photoreceptors that precede cell death (Zhang et al., 2008; Enzsoly et al., 2014) . For the most part there appears to be a consensus that a protracted period of diabetes leads to reduction in retinal thickness in a variety of animal models (Clermont et al., 2011; Yang et al., 2013) .
Evidence of neurodegeneration from clinical imaging studies confirms the histological results from animal models of diabetes
The significance of apoptosis and progressive loss of cells in the retina in animal models of diabetes was difficult to determine. Apoptosis is a transient event so the number of TUNEL-positive cells A.J. Barber, B. Baccouche Vision Research 139 (2017) 82-92 was very small and difficult to quantify accurately. The chronic degeneration has, however, been confirmed by numerous clinical imaging studies that implicate neurodegeneration, especially of the inner retinal layers, as an early event in DR. Significant reductions in retinal layer thicknesses were found even in patients with little or no evidence of vascular retinopathy. Scanning laser polarimetry (SLP) was initially used to identify a significant reduction in the thickness of the retinal nerve fiber layer in a small group of Type 1 diabetic patients without microvascular complications (Lopes de Faria, Russ, & Costa, 2002) . A similar but larger study using SLP also reported significant thinning of the nerve fiber layer (Ozdek, Lonneville, Onol, Yetkin, & Hasanreisoglu, 2002) . A more extensive study of Type II diabetic patients confirmed the thinning of the retinal nerve fiber layer (Takahashi et al., 2006) . These studies strongly suggested that diabetes leads to a gradual loss of retinal ganglion cells, and consequently a reduction in the number of axons making up the nerve fiber layer. More recently, spectral domain optical coherence tomography (SD-OCT) imaging technology has provided a higher resolution approach useful in clinical diagnosis and research for many retinal diseases, which can be used to obtain accurate measurements of the thickness of retinal cell layers. SD-OCT was used to show significant thinning of the nerve fiber layer in the superior quadrants of the retina in a small number of patients with Type II diabetes (Sugimoto et al., 2005) . A Further study of patients with Type I diabetes also revealed a statistically significant retinal thinning of the pericentral area around the fovea in patients with minimal DR (Biallosterski et al., 2007) . While the retinal thickness of the diabetic patients in this study was only about 5% less than that of the healthy subjects, the results indicated a potential early loss of retinal ganglion cell axons in an important region of the macula.
Other SD-OCT studies have identified thinning of the nerve fiber layer in a mixed population of Type I and Type II diabetic patients, which correlated with fasting blood glucose levels (Peng, Lin, & Lin, 2009) . A similar but higher resolution study also found a differential reduction in the thickness of the combined ganglion cell and inner plexiform layer (by 2.7 µm loss), and a smaller loss of the inner nuclear layer in diabetic patients (van Dijk et al., 2009 ). The reduction was limited to the pericentral region of the macula, while more peripheral regions were unaltered. It also appears that the peripheral retina is not completely spared, because a follow-up study reported significant reduction of the peripheral macula nerve fiber layer (3.7 µm loss) accompanied by a greater loss of tissue in the pericentral ganglion cell layer (5.1 µm loss) (van Dijk et al., 2010) . Again the Type I diabetic patients in this study had minimal evidence of vascular retinopathy. Other investigators found similar changes in the retinal nerve fiber layer within the central macula, in Type I and Type II diabetic patients (Cabrera DeBuc & Somfai, 2010; van Dijk et al., 2012) . There was also a significant correlation between ganglion cell layer thickness and the duration of diabetes, suggesting that the degeneration becomes more extensive with time. Other studies have established correlations between the macular and foveal thickness and the duration of diabetes (Asefzadeh, Fisch, Parenteau, & Cavallerano, 2008; Araszkiewicz et al., 2012) . Diabetic patients with no clinically detectible macular edema also had a significant reduction in the thickness of the retinal nerve fiber layer (Vujosevic & Midena, 2013) . This study detected an unexpected increase in the thickness of the inner plexiform and nuclear layers, which the authors suggested was due to Müller cell inflammation and swelling, presumably as a precursor to edema. SD-OCT has also been used to identify sex differences in the central macular thickness in both healthy and diabetic patients, being slightly thicker in males (Browning, Fraser, & Clark, 2008) . Although another study found no significant difference in macular and nerve fiber layer thicknesses between healthy men and women and a greater reduction in thickness in women with diabetes compared to men (Oshitari, Hanawa, & AdachiUsami, 2009 ).
It is unclear whether the small loss of inner retina tissue revealed by SD-OCT has relevance to loss of visual function because few diabetes studies have attempted to measure function alongside retinal morphology. One study, however, showed that the structural changes in retinal thickness were accompanied by delays in the multifocal ERG as well as abnormal venular dilation in adolescents with Type II diabetes (Bronson-Castain et al., 2009 ). Another study found that the ganglion cell layer thickness predicted subtle deficits in visual function measured by the Rarebit perimetry and fovea test, which is sensitive to small changes in visual acuity (Frisen, 2002; van Dijk et al., 2011) . The small number of correlative studies so far indicate that the subtle reductions in nerve fiber and retinal ganglion cell layers do have an impact on visual function that can be measured in the clinical setting. More work of this type is imperative because it will give rise to more sensitive approaches to early diagnosis. Recent SD-OCT studies have further refined the estimates of tissue loss in the inner retina and reported thinning of the nerve fiber layer and retinal ganglion cell layer in both Type I and Type II diabetic patients (Demir, Oba, Sensoz, & Ozdal, 2014; Chhablani et al., 2015; Frydkjaer-Olsen, Soegaard Hansen, Pedersen, Peto, & Grauslund, 2015; Tavares Ferreira et al., 2017) . Even children with Type I diabetes were found to have inner retinal thinning despite the lack of detectible vascular pathology in these patients (El-Fayoumi, Badr Eldine, Esmael, Ghalwash, & Soliman, 2016) .
The rapid increase in clinical research using SD-OCT has validated the older histological measurements of inner retina degeneration from the diabetic animal models and establish the tissue loss as a progressive pathology (De Clerck et al., 2015; Sohn et al., 2016) . Reductions in the thickness of the nerve fiber layer are most likely due to loss of retinal ganglion cell axons, which presumably includes the loss of cell bodies and dendrites. The loss of neural tissue is likely to compromise the information processing capacity of the inner retina and ultimately limit the ability to transmit visual information to the brain. In most studies the reduction in thickness of the nerve fiber layer was apparent in patients that did not have macular edema, suggesting that significant neural degeneration occurred before a clinically apparent fluid accumulation. Furthermore, many of these clinical studies were in patients with mild or no vascular retinopathy, suggesting that clinically measurable neurodegeneration is an early event and not a consequence of vascular pathology. Finally, a comprehensive 4-year longitudinal study of Type I and Type II diabetic patients recently concluded that the thinning of the retinal nerve fiber layer, ganglion cell layer, and inner plexiform layer is progressive; occurring at a rate of 0.29 µm/year and beginning in the absence of vascular pathology (Sohn et al., 2016) .
4.
In Vivo imaging can also be used to detect changes in retinal thickness in animal models of diabetes Fewer studies have used in vivo imaging to examine animal models of diabetes. But reduction in the thickness of the diabetic mouse retina was measured by MRI (Berkowitz, Gradianu, Bissig, Kern, & Roberts, 2009 ). Since then the recent increase in availability of SD-OCT devices adapted for animals has made possible several studies confirming the previous histological observations. There was a significant reduction reported in the thickness of the retinal nerve fiber layer and total retinal thickness in Otsuka Long-Evans Tokushima fatty rats, a model of Type II diabetes (Yang et al., 2013) . Also, SD-OCT imaging revealed a significant reduction in the combined thickness of the nerve fiber and inner plexiform layers in 22-week-old leptin-deficient mice, another model of Type II diabetes (Zhi et al., 2014) . Although a study on the Ins2
Akita mouse reported no significant changes in retinal thickness using SD-OCT and histological cross sections (McLenachan, Chen, McMenamin, & Rakoczy, 2013) , this was despite earlier histology studies showing a significant reduction in the thickness of the inner layers of the Ins2 Akita mouse retina (Barber et al., 2005) . Further SD-OCT studies reported that Ins2 Akita diabetic mice did have a progressive thinning of the inner retina which became apparent 3 months after the A.J. Barber, B. Baccouche Vision Research 139 (2017) 82-92 onset of hyperglycemia (Hombrebueno, Chen, Penalva, & Xu, 2014; Cahoon et al., 2015) . The discrepancies between these results are difficult to explain but wide variations in the degree of retinal pathology between Ins2 Akita mouse colonies have been observed and the cause of these variations remains undetermined (Akimov & Renteria, 2012; Smith et al., 2008; Umino & Solessio, 2013) . Careful consideration must be given to the changes within individual cell layers when using SD-OCT, since a recent study using Long-Evans rats after 15 weeks of STZ-diabetes demonstrated both a 10% reduction in the ganglion cell and inner plexiform layer and an equivalent increase in the thickness of the outer nuclear and photoreceptor layers, indicating that neurodegeneration of the inner retina may be accompanied by swelling (possibly due to edema) of the outer retina (Barber & Nasralah, 2016) . A previous MRI study also suggested that retinal edema can be detected in vivo in diabetic Sprague-Dawley rats after 2 months of hyperglycemia (Berkowitz et al., 2012) . Therefore, in vivo imaging of diabetic animal models may reveal both retinal neurodegeneration and swelling due to edema, and both can potentially occur simultaneously during later stages of the disease, leading to difficulties in interpreting measurements of total retinal thickness. Accurate measurement of individual cell layers as well as total retinal thickness is imperative in this type of study.
Other features of neurodegeneration found in retinas of diabetic animal models

Abnormalities in neuronal morphology
Aside from neuronal apoptosis and tissue loss, neurodegenerative diseases can have other features including changes in neuronal morphology and function. The death of a cell is the final event in a series of alterations to its morphology and biochemistry which may last for a protracted period of time. Studies suggest that diabetes can induce some of these other changes in the neurons of the retina including alterations in morphology. By using a gene gun to label neurons with DiI it was shown that some retinal ganglion cells had enlarged dendritic fields (Qin, Xu, & Wang, 2006) . A study of the Ins2 Akita mice crossed with transgenic Thy1-YFP mice, which express yellow fluorescent protein throughout the cytoplasm of a random subset of retinal ganglion cells, revealed a number of pathological features including axonal varicosities associated with axon thinning. The large ON-ganglion cells of these mice also had abnormalities including a significantly greater density of dendrites, with some that appeared to extend beyond the normal dendritic field of the cell (Gastinger et al., 2008) . Similar histological features in retinal ganglion cells were also described in a postmortem study using DiI to label ganglion cells in a small number of postmortem human retinas (Meyer-Rusenberg et al., 2007) . It is possible that the increase in retinal ganglion cell dendrite arborization may be a plastic response to compensate for loss of input from neighboring amacrine and bipolar cells that have previously undergone apoptosis (Gastinger et al., 2006) . It is possible that the changes in retinal ganglion cell morphology are accompanied by altered function. The spontaneous spiking activity of ON-type retinal ganglion cells is elevated in STZ-diabetic mice, measured by single cell recoding, possibly due to loss of inhibitory input to these cells (Yu, Wang, et al., 2013) . Quantitative studies of dendrite morphology are rare because they are painstakingly difficult, and single cell functional studies are even more technically challenging. But the small number of studies that have been performed suggest that diabetes causes changes in the morphology and functional output of retinal ganglion cells, possibly as a consequence of the loss of input from other retinal neurons and a precursor to cell death.
Effects of diabetes on photoreceptors
The degeneration of neurons may not be limited to the inner retina.
The morphology and survival of photoreceptors may also be altered by diabetes. Postmortem retinas obtained from donors with different stage of DR showed selective damage of S-cones using TUNEL and carbonic anhydrase staining (Cho, Poulsen, Ver Hoeve, & Nork, 2000a) . Tissue from donors with DR also had a selective reduction in the density of Scones (Cho, Poulsen, Ver Hoeve, & Nork, 2000b) , and deficits in blueyellow contrast sensitivity are evident in patients with diabetes, suggesting an imbalance between different cone populations (Rockett, Anderle, & Bessman, 1987) . Recently, images captured with an adaptive optics retinal camera also indicated a decrease in cone density among type-2 diabetic patients with advanced stages of DR . Some studies have also reported photoreceptor pathology in diabetic animals. A dramatic loss of photoreceptors was progressively detected by TUNEL beginning 4 weeks after STZ-diabetes induction in rats (Park et al., 2003) , although the extent of cell death in this study does not match with what is known from clinical specimens. In 3-month old diabetic Ins2Akita mice, a 10% loss of the S-cones was reported more recently (Hombrebueno et al., 2014) . Structural changes in photoreceptors may also precede cell death in STZ-diabetic rats (Enzsoly et al., 2014) . Photoreceptor function measured by paired-flash ERG also appears to be altered within days after the induction of hyperglycemia (Phipps, Fletcher, & Vingrys, 2004) .
Retinal ganglion cell axons and the optic nerve
The morphological changes to retinal ganglion cell axons include swelling of some axons and thinning close to the retinal ganglion cell body (Gastinger et al., 2008) . The varicosities associated with axon thinning previously noted in retinas of diabetic mice could be explained by accumulation of molecular material at points of axon transport failure (Gastinger et al., 2001; Gastinger et al., 2006) . Some investigators have noted difficulties in labeling retinal ganglion cells by retrograde uptake of dye in diabetic rodents, presumably indicating failure of axonal transport in the optic nerve. Fluoro-gold injection into the dorsal lateral geniculate nucleus was transported to a smaller number of retinal ganglion cell bodies in diabetic rodents compared to controls (Zhang, Inoue, Dong, & Yamamoto, 1998) . The effect appeared to be limited to the axons of large and medium ganglion cells and was reduced by an aldose reductase inhibitor (Ino-Ue, Zhang, Naka, Kuriyama, & Yamamoto, 2000; Zhang, Ino-ue, Dong, & Yamamoto, 2000) . Anterograde transport of fluorescently labelled cholera toxin from the retina to the superior colliculus was also significantly reduced in diabetic rats, suggesting that transport deficits occur in both directions along the axon (Dorfman, Aranda, & Rosenstein, 2015) . There is also evidence that the number of axons in the optic nerve is diminished, while glial numbers may increase (Scott, Foote, Peat, & Galway, 1986; Howell et al., 2013) , suggesting that loss of retinal ganglion cell bodies may be accompanied by degeneration of their axons. These studies suggest that loss of neuronal function and neurodegeneration is not limited to the retina but also impacts the axons that make up the optic nerve.
Reduced expression of synaptic proteins
Synapses are the functional features that allow neurons to communicate with each other. It follows that any change in synaptic morphology or protein content could impact the way a neuron behaves within a network and if the deficit in synaptic number or efficiency is large enough it could alter the information processing ability of the neural network. Histological studies showing reductions in the thickness of the inner plexiform layer or inner nuclear layers, described earlier, imply an alteration in the dendritic structure of neurons that could include loss of synaptic connectivity Gaspar et al., 2010) . These studies suggested either a reduction in the total number of synapses within the inner retina, or a reduction in the expression of proteins that make up the machinery required for neurotransmission. Some of the same synaptic proteins were found to be depleted in the hippocampus of diabetic rats, suggesting the possibility that diabetes may alter synaptic protein regulation in the brain as well as the retina (Gaspar et al., 2010) .
The diabetes-induced reduction in synaptic proteins was corrected by insulin, but only if the treatment was initiated soon after the onset of diabetes. When insulin was given after a more protracted period of diabetes, the synaptic protein content was not returned to control levels (Masser et al., 2014) . The implication of this study is that the initial phase of synaptic protein loss is reversible and is likely due to a metabolic defect, whereas the more chronic deficit is permanent and may be due to irreversible cell death. A biochemical study of the regulatory mechanisms of synaptophysin synthesis confirmed the possibility that the reduction in protein content may initially be metabolic in nature. Explant retinas from diabetic and control rats were labeled with 35 Smethionine to determine changes in the rate of synthesis of synaptophysin (D'Cruz et al., 2012). The study found an imbalance between the rate of mRNA translation and post-translational mannosylation of synaptophysin protein, and a reduction in the content of mature synaptophysin. The results suggested that the diabetes-induced decrease in synaptophysin is due to failed post-translational processing of the protein. Another study found that the angiotensin system can also regulate synaptophysin synthesis and degradation (Kurihara et al., 2008) . , including a study showing that placing STZ-diabetic rats in an enriched environment can prevent the reduction in synaptophysin and other markers of retinal degeneration. The potential mechanism for this effect may be complex in nature, involving changes in neurotrophin expression in the brain as well as potential changes in retinal synaptic activity (Dorfman et al., 2014a) . Alterations in synaptic structure and abundance are likely to impact the information processing capabilities of each neuron in the network, ultimately changing the network output. While it is unclear how much loss of synaptic protein is required to have a clinically significant effect on vision, the long term consequence of changes in synaptic protein expression cannot be dismissed.
Changes in neurotransmitter content and function
Electrophysiological abnormalities are among the earliest manifestations of DR. In patients with DR (with a history of diabetes of 5 years), rod and cone photoreceptor function examined by electroretinogram (ERG) was found to have rod and cone transduction abnormalities (Holopigian, Greenstein, Seiple, Hood, & Carr, 1997) . Studies using ERG revealed alterations in retinal electrical responses of short-term diabetic rats. In STZ-diabetic rats, retinal function was gradually affected from 2 weeks after the onset of hyperglycemia (Li, Zemel, Miller, & Perlman, 2002) . B-wave, OPs, and a-wave amplitudes were significantly reduced from 5 to 10 weeks of hyperglycemia (Li, Zemel, Miller, & Perlman, 2001; Kohzaki, Vingrys, & Bui, 2008; Dorfman et al., 2014b) . Moreover, ERG studies revealed a significant decrease of a-wave, b-wave, and ∑OPs amplitudes with prolonged implicit times after 24 weeks of hyperglycemia in type-2 diabetic OLETF rats (Hotta et al., 1997) and bwave amplitude was significantly reduced in db/db mice at 16 and 24 weeks (Bogdanov et al., 2014) . Other electrophysiological approaches have shown that the scotopic threshold response is reduced in both mice and rats with diabetes (Kohzaki, Vingrys, Bui, Kohzaki, et al., 2008; Ha et al., 2012) , suggesting a loss of retinal ganglion cell and amacrine cell function and confirming earlier clinical studies (Abraham, Haimovitz, & Berezin, 1988; Aylward & Billson, 1989; Papakostopoulos, Hart, Corrall, & Harney, 1996) . Finally, spontaneous activity of individual ON-type retinal ganglion cells has been shown to increase in STZ-diabetic rats, measured by single-cell recording, indicating a disinhibition of these cells possibly as a result of amacrine cell dysfunction (Yu, Wang, et al., 2013) .
The functional and electrophysiological deficits in diabetes may be explained by morphological changes but could also be in-part due to alterations in the neurotransmitter systems of the retina. Neurotransmitter release and uptake is critical to healthy function in the central and peripheral nervous system and loss of synaptic proteins associated with neurotransmitter vesicle stabilization, transport and membrane docking is also likely to alter neurotransmitter release. Neurotransmission is noted to change in chronic neurodegenerative diseases, and there is an accumulation of evidence that diabetes causes the dysregulation of several neurotransmitters in the retina. Furthermore, several classes of drugs could be used to modulate the neurotransmitter systems of the retina in an attempt to correct some of the deficits in visual function, as outlined below.
Glutamate
Glutamate is an important neurotransmitter in neurodegenerative disorders because of its excitatory effect on neurotransmission, which can lead to excitotoxicity when an abnormal amount of glutamate is released, causing excessive depolarization of neighboring neurons. Glutamate is the primary neurotransmitter in the retina and is highly abundant, being released in large quantities by photoreceptors, especially in the dark. Several publications have indicated that the storage, release and metabolism of retinal glutamate is disrupted by diabetes. Early work showed that the total retinal content of glutamate is elevated by diabetes (Ambati et al., 1997; Lieth et al., 1998; Kowluru, Engerman, Case, & Kern, 2001) , and that this may be due to a failure of glutamate metabolism through reduced glutamine synthase activity in Müller cells (Lieth, LaNoue, Antonetti, & Ratz, 2000) . Reduced uptake of glutamate into Müller glia is also likely to compound the metabolic failure (Li & Puro, 2002; Puro, 2002) , although another study found a potential increase in glutamate uptake (Ward, Jobling, Kalloniatis, & Fletcher, 2005) . Neurotransmission can also be affected by receptor abundance and several studies have shown that the expression of various glutamate receptors is altered by diabetes. A histological study reported upregulation of NMDA and GluR2/3 in retinas of STZ-diabetic rats (Ng, Zeng, & Ling, 2004) . A similar study of human retinas also found increased expression of the NMDA receptor and several GluR subunits (Santiago, Hughes, Kamphuis, Schlingemann, & Ambrosio, 2008) . Other experimental studies have found both increases and decreases in a variety of GluR and NMDA receptor subunits, as well as other genes related to glutamate neurotransmission; indicating a complex pattern of changes that is also dependent on the duration of diabetes (Santiago et al., 2009; Lau, Kroes, Moskal, & Linsenmeier, 2013) .
While data show that retinal glutamate signaling is disrupted by diabetes it is still unclear whether glutamate or its receptors could be a potential therapeutic target. Memantine is a weak NMDA receptor antagonist that is thought to reduce the excitotoxic effects of excess glutamate and is used to treat early stage Alzheimer's disease. It has recently been shown to protect neurons in the retina in a variety of disease models including ischemia and glaucoma (Yigit et al., 2011; Abdel-Hamid, Firgany Ael, & Ali, 2016; Celiker et al., 2016) . Memantine was also shown to prevent NMDA-induced elevation of TBARS and NO, which can be used as markers of oxidative stress, in explant rat retinas (Kowluru et al., 2001 ). Furthermore, one study has shown that memantine protected electrophysiological retinal function and reduced vascular leakage in STZ-diabetic rats (Kusari, Zhou, Padillo, Clarke, & Gil, 2007) , but there have been no comprehensive studies published to further promote this drug as a potential therapy for DR.
Gamma-aminobutyric acid
Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter produced by amacrine cells in the retina, and appears to be elevated by diabetes, possibly explaining the reduced amplitude of certain components of the electroretinogram (Ishikawa, Ishiguro, & Tamai, 1996; Ambati et al., 1997; Ramsey, Ripps, & Qian, 2006) . Although other studies have also reported decreases in retinal GABA concentrations (Honda, Inoue, Okada, & Yamamoto, 1998) , a patch clamp study revealed that diabetes increases the sensitivity of the GABA(c) receptor on bipolar cells (Ramsey, Ripps, & Qian, 2007) . Recently an elegant electrophysiological study of the rod bipolar-AII-A17 amacrine micro-circuit suggested that reduced Ca +2 permeability of AMPA receptor channels results in reduced release of GABA from the amacrine cells, causing a disinhibition of this negative feedback system and an increase in glutamate release from the rod bipolar cells, which could result in abnormal inner retina signal processing (Castilho, Ambrosio, Hartveit, & Veruki, 2015) . AMPA receptors in the retina may therefore represent valid pharmacological targets to correct visual dysfunction in DR.
Dopamine
Changes in dopamine signaling in the brain are commonly associated with Parkinson's disease, but a subset of amacrine cells in the retina also release dopamine and play a role in signal processing in the retina. Early observations of reductions in dopamine content (Nishimura & Kuriyama, 1985) , may be explained by reductions in tyrosine hydroxylase, a marker for dopaminergic amacrine cells and the key enzyme in dopamine synthesis. Degeneration of amacrine cells and reduction in tyrosine hydroxylase immunoreactivity has been reported in hyperglycemic sand rats and in STZ-diabetic rats (Larabi, Dahmani, Gernigon, & Nguyen-Legros, 1991; Seki et al., 2004) . Quantitative immunohistochemistry using tyrosine hydroxylase found significant loss of amacrine cells in Ins2
Akita diabetic mice and in STZ-diabetic rats (Gastinger et al., 2006; Lahouaoui, Coutanson, Cooper, Bennis, & Dkhissi-Benyahya, 2016) . Augmentation of the dopaminergic system by administration of L-DOPA, the precursor of dopamine synthesis used to treat Parkinson's disease, improved visual function measured by the optomotor tracking reflex in diabetic mice. The results suggest that this early loss in dopaminergic cells may account for loss of contrast sensitivity during the early stages of DR, and that augmentation of retinal dopamine signaling with L-DOPA or dopamine receptor agonists, may normalize some of the early deficits in visual function (Aung et al., 2014) . Other drugs have been used to slow Parkinson's disease and could also be tested for effectiveness in treating neurodegeneration in DR. The mono amine oxidase-B (MAO-B) inhibitors selegeline ((-)deprenyl) and rasagiline are used to augment L-DOPA therapy by preventing glial metabolism of dopamine after neurotransmission, thus increasing the availability of the neurotransmitter. But (-)deprenyl has also been shown to have neuroprotective properties separate from its MAO-B inhibitory action, most likely by preventing nuclear translocation of GAPDH during apoptosis (Paterson, Barber, Gelowitz, & Voll, 1997; Paterson, Zhang, Warrington, & Boulton, 1998; Weinreb, Amit, BarAm, & Youdim, 2010; Zhao, Cai, & Bai, 2013) . (-)Deprenyl reduced systemic markers of oxidative stress while increasing superoxide dismutase, and also decreased nitric oxide synthase in heart tissue of diabetic rats (Alper, Irer, Duman, Caglayan, & Yilmaz, 2005; Irer et al., 2007) . (-)Deprenyl has also been shown to protect retinal Müller cells, immortalized retinal neurons, and ARPE-19 cells from apoptosis in vitro (Ragaiey et al., 1997; Xu, Ma, Seigel, & Ma, 1999; Kusner, Sarthy, & Mohr, 2004; Surgucheva, Ninkina, Buchman, Grasing, & Surguchov, 2005) , and protected rat retinas against NMDAinduced excitotoxic injury (Takahata et al., 2003) . Other aliphatic propargylamine drugs based on (-)deprenyl, but lacking the MAO-B inhibition properties, may have more potent neuroprotective action (Yu et al., 1994; Berry & Boulton, 2002 ), but to our knowledge this class of drugs has not been tested for their effectiveness to prevent diabetesinduced neurodegeneration of the retina.
Acetylcholine
The accelerated cell death is not limited to the dopaminergic amacrine cells, but also applies to cholinergic cells, which were reported to be depleted in Ins2
Akita mice (Gastinger et al., 2006) . Earlier studies showed decreased cholinesterase activities in diabetic rats (SanchezChavez & Salceda, 2000; Sanchez-Chavez & Salceda, 2001) , suggesting a reduction in the synthetic capacity for acetylcholine neurotransmitter in diabetic rat retina. Acetylcholine and acetylcholine receptor agonists have been used to protect retinal ganglion cells in models of retinal excitotoxicity (Thompson, Smith, Linn, & Linn, 2006; Iwamoto, Mata, Linn, & Linn, 2013) but there are no studies testing potential agents to protect the cholinergic amacrine cells of the retina in diabetes.
6. Potential novel therapeutic approaches to retinal neuroprotection in diabetes 6.1. Cardiolipin
One potentially interesting molecular target in diabetes-induced retinal degeneration is cardiolipin, an abundant lipid in the inner mitochondrial membrane, where it appears to facilitate the function of the enzymes of the electron transport chain. It also becomes part of the apoptosis cascade by migrating from the inner to outer mitochondrial membrane (Paradies, Petrosillo, Paradies, & Ruggiero, 2009 ). Currently there is little evidence for a direct role of cardiolipin in diabetic retinal neurodegeneration, however a small number of patients with proliferative DR were found to have circulating cardiolipin antibodies, suggesting this as a risk factor for DR (Shahin, El-Diasty, & Mabed, 2009 ). More recently the drug MTP-131 (also known as SS-31), a water soluble peptide that targets cardiolipin, was shown to protect visual function in diabetic mice (Alam et al., 2015) . It is hoped that there will be further studies to test the effectiveness of cardiolipin inhibition on DR.
Lipoic acid
One therapy that has been suggested to treat neurodegeneration in Alzheimer's disease is lipoic acid. Alpha-lipoic acid (ALA) is a naturally occurring coenzyme involved in regulating mitochondrial metabolism (Liu, 2008) . ALA appears to possess potent antioxidant properties, and can be absorbed from the gastrointestinal tract and cross the bloodbrain barrier. It has been suggested to improve cognitive function in Alzheimer's disease in both experimental and clinical studies (Packer, Tritschler, & Wessel, 1997; Liu, 2008; Maczurek et al., 2008) .
There have been several studies testing ALA in diabetes. A crosssectional experiment provided evidence that treatment with ALA normalized parameters of oxidative stress in the plasma of diabetic patients (Borcea et al., 1999) . Other experimental studies demonstrated that ALA supplementation was able to protect the lens of STZ-diabetic rats and restore retinal ganglion axon transport and axon number in a mouse model of glaucoma (Kojima et al., 2007; Inman, Lambert, Calkins, & Horner, 2013) . Long term ALA administration reduced the pericyte loss and the increase in acellular capillaries in diabetic rat retina (Lin et al., 2006; Kowluru & Odenbach, 2004) . ALA also corrected abnormal intra-retinal manganese uptake measured by magnetic resonance imaging in STZ-diabetic rats, suggesting that it can normalize diabetes-induced changes in Ca +2 signaling (Berkowitz, Roberts, Stemmler, Luan, & Gradianu, 2007) . Some evidence also suggests that ALA restores retinal function and is protective against microvascular dysfunction in the retinas of diabetic mice (Johnsen-Soriano et al., 2008) . Recently a study on STZ diabetic mice showed that treatment with ALA may prevent retinal ganglion cell loss and thinning of the inner A.J. Barber, B. Baccouche Vision Research 139 (2017) 82-92 retina (Kan, Alici, Kan, & Ayar, 2016) . ALA antioxidant capacities contribute to the protection of the diabetic retina via modulation of the glycation and hexosamine pathways (Packer, Kraemer, & Rimbach, 2001; Lin et al., 2006) . ALA also prevents lipid peroxidation by interacting with glutathione and antioxidant defense enzymes such as glutathione peroxidase in the diabetic retina (Obrosova, Fathallah, & Greene, 2000) . A clinical study suggests that the administration of ALA promotes visual acuity in T1DM and T2DM patients (Gebka, Serkies-Minuth, & Raczynska, 2014) . There is an opportunity for further clinical and experimental work to establish the effectiveness of ALA to prevent neurodegeneration and loss of visual function in diabetes.
Carotenoids
One potential form of therapy that has recently received some attention is the carotenoid group of dietary pigments. Carotenoids have a broad spectrum of biological activities and potential to modulate degenerative diseases. The carotenoids are natural pigments synthetized by some microorganisms and plants and include α-carotene and β-carotene, lutein, zeaxanthin and lycopene. Carotenes and xanthophyll are detected in human plasma (Barua & Furr, 1992; Khachik, Beecher, Goli, Lusby, & Smith, 1992) , where they are transported by blood lipoproteins (Clevidence & Bieri, 1993; Parker, 1989; Loane et al., 2008) . The association between plasma carotenoid concentrations and DR suggest their potential use by dietary intervention (Brazionis, Rowley, Itsiopoulos, & O'Dea, 2009; Hu, Hu, Lin, Ma, & Li, 2011) .
To evaluate the effect of dietary carotenoids in degenerative disease progression, several rodent models have been explored including ischemia/reperfusion and acute glaucoma (Cort et al., 2010; Li et al., 2012) , as well as chemical and spontaneous models of DR (Kowluru, Menon, & Gierhart, 2008; Dong et al., 2013; Yeh, Huang, Yang, Yang, & Yang, 2016) . The blood retinal barrier allows carotenoids to enter the retina, since lutein, zeaxanthin and lycopene can be detected in ocular tissue (Khachik, Carvalho, et al., 2002; Khachik, de Moura, Zhao, Aebischer, & Bernstein, 2002) . The macular pigments lutein and zeaxanthin are present in the lipid membrane bilayers or associated with xanthophyll binding proteins and are thought to aid normal vision by protecting photoreceptors from phototoxic blue light (Yemelyanov, Katz, & Bernstein, 2001; Khachik, de Moura, et al., 2002; Bhosale et al., 2004; During, Doraiswamy, & Harrison, 2008; Li, Vachali, Frederick, & Bernstein, 2011) . Zeaxanthin and astaxanthin also modulate the activity of the transcription factor nuclear factor-kappaB (NF-κB), inflammatory mediators (ICAM-1, MCP-1) and vascular endothelial growth factors in retina and the vitreous (Kowluru et al., 2008; Yeh et al., 2016) .
In the diabetic retina, carotenoids tend to protect retinal mitochondrial function from hyperglycemia induced-stress by promoting the cytochrome bc complex and manganese superoxide dismutase activities (Dong et al., 2013; Kowluru et al., 2008; Tang et al., 2011) . To maintain the integrity of the mitochondrial membrane, carotenoids target the Bcl-2 family of proteins and prevent cytochrome c release (Chucair et al., 2007; Wolf et al., 2010; Dong et al., 2013) . Lutein and zeaxanthin could also provide protection against hypoxia, enhance mitochondrial biogenesis, and prevent the increased expression of the endoplasmic reticulum stress biomarkers (Yu, Wark, et al., 2013) . Zeaxanthin, lutein and astaxanthin promote the survival of neuronal cells in the inner layer of the retina by reducing the incidence of apoptosis (Ozawa et al., 2012; Dong et al., 2013) and attenuate Müller cell inflammation (Li et al., 2012) . Xanthophyll carotenoids ameliorate visual impairment (Li et al., 2009; Choi, Kang, Yang, Lee, & Shin, 2011; Yeh et al., 2016) and prevent retinal capillary cell apoptosis . Furthermore, dietary supplementation with lutein and zeaxanthin in patients with non-proliferative DR may protect visual function (Hu et al., 2011; Zhang et al., 2016) .
Nuclear factor (erythroid-derived 2)-like 2
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and nuclear factor-κB (NF-κB) are the two key transcription factors that regulate cellular responses to oxidative stress and inflammation (Wardyn, Ponsford, & Sanderson, 2015) . The endogenous antioxidant defense system plays an important role in the protective mechanisms to reduce retinal degeneration. Under oxidative stress, Nrf2 is released from the inhibitory protein Keap1 and translocates to the nucleus to induce the expression of numerous genes. The Nrf2-antioxidant response element transcription pathway controls the expression of a battery of defensive genes crucial to the detoxification and elimination of reactive oxygen species (Kaspar, Niture, & Jaiswal, 2009) .
Nrf2 has been implicated as playing an important protective role in the retina and its activity appears to be compromised by diabetes, possibly because of epigenetic modifications to KEAP1 that alter its binding properties (Zhong, Mishra, & Kowluru, 2013; Mishra, Zhong, & Kowluru, 2014) . Also, diabetic Nrf2 knock-out mice have worsened visual dysfunction and accelerated loss of blood-retinal barrier integrity, indicating the important protective role for Nrf2 . Pharmacological enhancement of Nrf2 activity could represent an exciting approach to novel therapy for DR. The xanthophylls mesozeaxanthin and astaxanthin enhance Nrf2 and activate the expression of the phase II enzyme heme oxygenase-1 (HO-1) in the diabetic retina (Zhongrui et al., 2013; Orhan et al., 2016; Yeh et al., 2016) . Other drugs, including dimethyl and monomethyl fumarate, also target Nrf2, and have been shown to be effective in reducing the relapse rate in patients with multiple sclerosis (Gold et al., 2012) . Dimethyl fumarate or other compounds that activate Nrf2 may be a promising approach to treating retinal neurodegeneration in diabetes.
Summary and conclusions
DR is a complex disease that involves pathological changes to many, if not all the cellular elements that make up the retina. While vascular lesions and breakdown of the blood-retinal barrier are central to the disease progression it is clear from evidence presented in this review that neurodegeneration also makes an important contribution to the disease and that this process begins soon after the onset of diabetes. The insidious loss of neurons is irreversible in all neurodegenerative diseases and the early onset of tissue loss in diabetes means that improved diagnosis and prevention should be key goals in the care of diabetic patients. The important lesson of the Diabetes Control and Complications Trial still rings true in the context of the neurodegenerative components of DR, such that early control of blood glucose is vital to the long-term health of the retina (The Diabetes Control, 1993) . Furthermore, the permanent loss of retinal ganglion cells and other neurons of the retina could explain the "metabolic memory" phenomenon in which an earlier period of hyperglycemia remains detrimental to vision regardless of a later period of improved glucose control (White et al., 2008) .
Recent studies of both animal models and humans using in vivo imaging techniques have established that parts of the neural retina, especially the inner retina and nerve fiber layer, are depleted and that the degeneration begins in the absence of gross vascular lesions. There is growing suspicion that DR may be considered as two separate pathologies affecting the retina. One is vasculopathy affecting the function and morphology of the major superficial vessels and capillary bed within the retina, leading to edema, capillary loss and ischemia. The other is a chronic neuropathy that leads to altered morphology of retinal ganglion cells, changes in neurotransmitter and synapse function and culminating in loss of neurons. The two components of the disease may or may not have a direct causal link, especially early in the disease process.
The current treatments for DR target the vascular pathology and are effective in reducing vasogenic edema due to increases in vascular permeability. Laser surgery remains a useful tool to target regions of ischemia that induce proliferating blood vessels. Retinal neurodegeneration, however, has not been widely considered as a therapeutic target. This may be because the current classes of neuroprotective drugs are not particularly effective in treating the major degenerative diseases of the brain, and at best can only slow disease progression. Also, major degenerative disorders of the central nervous system, such as Parkinson's and Alzheimer's disease, are difficult to detect in their early stages, so preventive intervention is not a fully viable option. Nevertheless, we can learn lessons from examining the progress in treating neurodegenerative disorders of the brain. In this review we have attempted to consider several potential drug approaches found in both the traditional pharmaceutical and the nutraceutical array. As we move towards developing a wider range of novel treatments for DR there is an opportunity to incorporate drugs that target neurotransmission and neuroprotection as adjunct therapies with existing treatments that reduce vascular permeability. With our broader appreciation of the multiple pharmacological targets presented by this complex disease we can be optimistic that effective prevention of vision loss in diabetes is closer to becoming a reality.
